Medicina
Departamento
Samsung Medical Center
Seúl, Corea del SurPublicaciones en colaboración con investigadores/as de Samsung Medical Center (7)
2021
-
RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non⇓small cell lung cancer
Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5258-5271
2020
-
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
Annals of Oncology, Vol. 31, Núm. 11, pp. 1526-1535
2019
2018
-
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: Patient-reported outcomes from the EMBRACA phase III trial
Annals of Oncology, Vol. 29, Núm. 9, pp. 1939-1947
-
Talazoparib in patients with advanced breast cancer and a germline BRCA mutation
New England Journal of Medicine, Vol. 379, Núm. 8, pp. 753-763
2015
2014
-
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review
International Journal of Oncology, Vol. 44, Núm. 1, pp. 5-16